Gastroenterology

pharma-news-for-biodexa-abbvie-insmed

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Immix Bio’s NXC-201 Gets FDA RMAT for AL Amyloidosis; Biodexa’s eRapa Wins Fast Track for Familial Adenomatous Polyposis; AbbVie’s EMBLAVEO Approved for Complicated Intra-Abdominal Infections; Insmed’s Brensocatib Gains Priority Review for Bronchiectasis; Aro Bio’s ABX1100 IND Cleared for Pompe Disease

Explore More...
pharma-news-for-agios-bridgebio-rigel

Agios’ PYRUKYND SNDA Accepted by FDA for Thalassemia; BridgeBio’s BBO-8520 Gets FDA Fast Track for KRASG12C-Mutated Lung Cancer; Nipocalimab Granted FDA Priority Review for Myasthenia Gravis; Rigel’s R289 Receives FDA Orphan Drug Designation for MDS; Rise Therapeutics Gets FDA IND Clearance for R-5780 in Cancer

From NASH to MASH: Unraveling the Evolution and Future of Liver Disease Treatment

Pharma-news-for-astellas-gsk-astrazeneca

Astellas & AviadoBio’s Exclusive Deal for AVB-101; GSK’s Depemokimab Shows Positive Results for Nasal Polyps; Lilly’s Mirikizumab Outperforms Ustekinumab in Crohn’s Study; TREMFYA Delivers Strong Results in Crohn’s & Colitis; ENHERTU Approved in China for HER2-Mutant NSCLC.

Advances in NASH Therapeutics Space

Advances in NASH Therapeutics Space: Latest Breakthroughs in Drug Development

Pharma-news-for-roche-johnson&johnson-regeneron

Johnson & Johnson’s TREMFYA Approved for Ulcerative Colitis; Roche’s Tecentriq Hybreza Approved as Subcutaneous Anti-PD-(L)1; OCREVUS ZUNOVO Receives Twice-a-Year Multiple Sclerosis Injection Approval; Lilly’s EBGLYSS Greenlit for Moderate-to-Severe Atopic Dermatitis; DUPIXENT Approved for Adolescents with Chronic Rhinosinusitis

Nonalcoholic Steatohepatitis (NASH) Highly Epidemic

Nonalcoholic Steatohepatitis (NASH): A Growing Epidemic

Meeting the Unmet Nonalcoholic Steatohepatitis (NASH)

Meeting the Unmet: Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic steatohepatitis Treatment Landscape Which Pipeline Therapy Will Steal the Spotlight

Nonalcoholic Steatohepatitis Treatment Market: Which Pipeline Therapy Will Steal the Spotlight?

NASH Emerging Therapies The Path Forward

NASH Emerging Therapies: The Path Forward

pharma-news-for-valneva-innovent-gsk-bayer

CEPI Grants $41.3 Million to Valneva; Innovent Achieves Phase III Success for Mazdutide; GSK’s BLENREP Combination Therapies EMA Review Application; Darolutamide Phase III ARANOTE Trial; Roche’s SUSVIMO Shows Long-Term Efficacy 

Eli Lilly acquired Morphic

Eli Lilly strengthening its Gastroenterology portfolio post Acquisition of Morphic. Tracking competitors and alliances in inflammatory bowel disease (IBD).

top-7-drugs-for-ulcerative-colitis-treatment

Top 7 Breakthrough Drugs for Ulcerative Colitis Treatment

pharma-news-for-eli-lilly-ideaya-roche-sanofi

Lilly’s Morphic Acquisition; IDEAYA’s IDE397 Positive Phase II Trial Result; XPOVIO (selinexor) Approval in China; Roche to Reintroduce Susvimo in the US; Dupixent EU Approval

medtech-news-for-asensus-surgical-allosource-abbott-foldax

Asensus Surgical Acquired by Karl Storz; Allosource® Launched Aceconnex®; Siemens Healthineers FDA Clearance for Chiller-Free Biograph Trinion PET/CT; Abbott Received FDA Clearance; Foldax® Reported Positive Clinical Results; Amber Implants Completed Enrolment of First-In-Human Clinical Trial

pharma-news-for-moderna-almirall-lilly-ipsen

Moderna’s Phase III Trials for Dual Influenza and COVID-19 Vaccine; Almirall’s Klisyri FDA Approval; Lilly’s Tirzepatide MASH Trial; Cycle Pharmaceuticals Acquisition of Vanda Pharmaceuticals; Ipsen’s Iqirvo FDA Approval

pharma-news-for-astrazeneca-biogen-altrubio-gsk

AstraZeneca’s Tropion-Lung01 Phase III Trial Positive Outcomes; Biogen’s LEQEMBI South Korea Approval; AltruBio’s $225M Series B Funding; GSK’s Depemokimab Positive Phase III Severe Asthma Results; Roche’s Inavolisib FDA Breakthrough Therapy Designation

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader